DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) reported Total Current Liabilities of $51.8 million for Q1 2026, up 28.27% year-over-year from $40.4 million in Q1 2025, and down 10.69% quarter-over-quarter from $58.0 million in Q4 2025.
DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 12 years of Total Current Liabilities data on file, last reported at $51.8 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $51.8 million, up 28.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.8 million (up 28.27% YoY), and the FY2025 annual result was $58.0 million, up 86.28% from the prior year.
- Total Current Liabilities slipped to $51.8 million in Q1 2026 per DBVT's latest filing, from $58.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $58.0 million in Q4 2025 and troughed at $26.0 million in Q1 2022.
- A 5-year average of $36.1 million and a median of $31.4 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 32.96% in 2022, then surged 86.28% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $29.5 million in 2022, then advanced by 26.48% to $37.3 million in 2023, then slipped by 16.61% to $31.1 million in 2024, then jumped by 86.28% to $58.0 million in 2025, then fell by 10.69% to $51.8 million in 2026.
- Business Quant data shows DBVT's Total Current Liabilities at $51.8 million in Q1 2026, $58.0 million in Q4 2025, and $49.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 51.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 58.00 Mn |
| Sep 30, 2025 | 49.49 Mn |
| Jun 30, 2025 | 49.43 Mn |
| Mar 31, 2025 | 40.38 Mn |
| Dec 31, 2024 | 31.14 Mn |
| Sep 30, 2024 | 30.91 Mn |
| Jun 30, 2024 | 27.38 Mn |
| Mar 31, 2024 | 26.48 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 31.44 Mn |
| Jun 30, 2023 | 33.37 Mn |
| Mar 31, 2023 | 32.78 Mn |
| Dec 31, 2022 | 29.52 Mn |
| Sep 30, 2022 | 28.39 Mn |
| Jun 30, 2022 | 30.43 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 31.40 Mn |
| Sep 30, 2021 | 33.81 Mn |
| Jun 30, 2021 | 38.70 Mn |